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TO THE EDITOR: In a recently published 
review on management of patients with 
biochemical failure (BF) following primary 
definitive therapy for localized prostate can-
cer (PCa), Darwish and Raj (2012) stated 
that following radical prostatectomy (RP) 
patients who are at high risk for recurrence 
after radiation therapy (RT), based upon a 
salvage nomogram, should be spared from 
this treatment modality justifying it by a 
range of toxicities it causes. Additionally, 
in the algorithm for management of BF 
after primary therapy they suggested that 
patients with a short prostate-specific 
antigen (PSA) doubling time (PSA-DT) 
and PSA > 10 ng/mL should not be offered 
salvage RT at all. Do these recommenda-
tions provide the optimal use of salvage RT 
following RP? Unfortunately, we feel that 
they do not.
While we agree with the authors that 
patients with higher PSA at the time of 
radiation (RT), short PSA-DT, high Gleason 
score, and other “bad” prognostic charac-
teristics do generally worse than patients 
without those features, it does not mean 
that salvage therapy should categorically 
not be discussed and potentially offered 
to patients at high risk of recurrence. As a 
matter of fact, in the study that was cited in 
the manuscript (Stephenson et al., 2007), 
select patients with some “bad” prognostic 
features did remarkably well after salvage 
RT. The 6-year progression-free estimate in 
patients with PSA-DT ≤ 10 months and GS 
8–10 with low PSA was 41%. When look-
ing at PSA-DT, in particular those with 
the shortest doubling time may be at the 
greatest risk for PCa-specific mortality 
(PCSM). Therefore, although salvage RT 
may be less likely to prevent recurrence 
in this group in the ones who are salvaged 
with RT the benefit may be profound. This 
is supported by the analysis from Trock 
et al. (2008) who found, in a retrospective 
analysis of 635 patients with BF after RP, 
that there was an increase in PCa-specific 
survival after salvage RT in patients with 
short PSA-DT ≤ 6 months only and not in 
those with a longer PSA-DT. Ina similar 
retrospective analysis of 432 patients with 
BF after RP, the beneficial effect of salvage 
RT on all-cause survival was more promi-
nent in patients with PSA-DT ≤ 6 months 
than in patients with PSA-DT > 6 months, 
with adjusted hazard ratios of 0.35 (95% 
CI 0.17–0.72, p = 0.042) and 0.6 (95% CI 
0.37–0.98, p = 0.04), respectively (Cotter 
et al., 2011). All these data suggest that 
salvage RT is effective and local control is 
still important in many patients with short 
PSA-DT, and PSA-DT should not be used 
to select patients that will not receive RT. As 
a result the suggestion by Darwish and Raj 
to avoid salvage RT in these patients would 
potentially deprive those with the great-
est relative benefit in regard to PCSM and 
overall survival from receiving this therapy.
Similarly, we disagree with the authors 
that “every salvage local therapy…for 
patients with BF is associated with a signifi-
cant risk of complications…” Late compli-
cations after adjuvant or salvage RT are well 
documented from prospective randomized 
trials and from retrospective series. The rate 
of severe side-effects ranges from low (all 
grade 3–4, ≤5%; Bolla et al., 2005; Pearse 
et al., 2008) to very low (<1%; Feng et al., 
2007; Wiegel et al., 2009) and should not 
preclude caretakers from offering this life-
saving treatment to their patients. While 
every treatment decision should be based 
on patient’s preferences and informed 
consent, one should remember how little 
benefit from toxic antineoplastic thera-
pies some patients will accept, when it is 
their only chance for cure. When consid-
ering adjuvant chemotherapy for early 
breast cancer (with less impressive HR for 
all-cause mortality (Early Breast Cancer 
Trialists’ Collaborative Group, 2005), and 
whose toxicities include death, life-threat-
ening infections, neuropathy, cardiomyo-
pathy, secondary cancers, infertility etc., a 
1%-improvement in the chance of cure, or 
additional life expectancy of 6 months were 
found to be sufficient by 50% of women 
to decide that adjuvant chemotherapy was 
worthwhile (Duric and Stockler, 2001). For 
a man with a rising PSA after RP the use 
of salvage RT is the only potentially cura-
tive therapy, it can be delivered with a low 
risk of long-term toxicities, and should be 
discussed with patients as part of multidis-
ciplinary management.
Further, we would support enrollment 
of these men on a number of key clinical 
trials now being evaluated in this setting 
which aim to further refine the impact of 
the timing of RT, the use, and duration of 
androgen deprivation therapy, and the use 
of pelvic RT in this critical patient popula-
tion (RADICALS; RTOG-0534). However, 
we would not, as the authors suggest, recom-
mend that these patients be recommended 
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to go directly to systemic therapy due to 
a misconception about both the potential 
benefits and likely harms of salvage RT.
RefeRences
Bolla, M., van Poppel, H., Collette, L., van Cangh, P., 
Vekemans, K., Da Pozzo, L., de Reijke, T. M., Verbaeys, 
A., Bosset, J. F., van Velthoven, R., Maréchal, J. M., 
Scalliet, P., Haustermans, K., and Piérart, M. (2005). 
Postoperative radiotherapy after radical prostatec-
tomy: a randomised controlled trial (EORTC trial 
22911). Lancet 366, 572–578.
Cotter, S. E., Chen, M. H., Moul, J. W., Lee, W. R., Koontz, 
B. F., Anscher, M. S., Robertson, C. N., Walther, P. J., 
Polascik, T. J., and D’Amico, A. V. (2011). Salvage 
radiation in men after prostate-specific antigen fail-
ure and the risk of death. Cancer 117, 3925–3932.
Darwish, O. M., and Raj, G. V. (2012). Management 
of biochemical recurrence after primary localized 
therapy for prostate cancer. Front. Oncol. 2:48 doi: 
10.3389/fonc.2012.00048
Duric, V., and Stockler, M. (2001). Patients’ preferences 
for adjuvant chemotherapy in early breast cancer: a 
review of what makes it worthwhile? Lancet Oncol. 
2, 691–697.
Early Breast Cancer Trialists’ Collaborative Group. (2005). 
Effects of chemotherapy and hormonal therapy for 
early breast cancer on recurrence and 15-year sur-
vival: an overview of the randomised trials. Lancet 
365, 1687–1717.
Feng, M., Hanlon, A. L., Pisansky, T. M., Kuban, D., Catton, 
C. N., Michalski, J. M., Zelefsky, M. J., Kupelian, P. A., 
Pollack, A., Kestin, L. L., Valicenti, R. K., DeWeese, 
T. L., and Sandler, H. M. (2007). Predictive factors 
for late genitourinary and gastrointestinal toxicity in 
patients with prostate cancer treated with adjuvant or 
salvage radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 
68, 1417–1423.
Pearse, M., Choo, R., Danjoux, C., Gardner, S., Morton, 
G., Szumacher, E., Loblaw, A., and Cheung, P. (2008). 
Prospective assessment of gastrointestinal and geni-
tourinary toxicity of salvage radiotherapy for patients 
with prostate-specific antigen relapse or local recur-
rence after radical prostatectomy. Int. J. Radiat. Oncol. 
Biol. Phys. 72, 792–798.
RADICALS. (2012). Radiotherapy and Androgen 
Deprivation in Combination after Local Surgery. 
Available at: http://www.radicals-trial.org (accessed 
August 30, 2012).
RTOG-0534. (2012). Prostate Radiation Therapy or 
Short-Term Androgen Deprivation Therapy and 
Pelvic Lymph Node Radiation Therapy with or without 
Prostate Radiation Therapy in Treating Patients With a 
Rising PSA after Surgery for Prostate Cancer. Available 
at: http://clinicaltrials.gov/show/NCT00567580 
(accessed August 23, 2012). 
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, 
T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., 
Michalski, J. M., Sandler, H. M., Lin, D. W., Forman, 
J. D., Zelefsky, M. J., Kestin, L. L., Roehrborn, C. G., 
Catton, C. N., DeWeese, T. L., Liauw, S. L., Valicenti, 
R. K., Kuban, D. A., and Pollack, A. (2007). Predicting 
the outcome of salvage radiation therapy for recurrent 
prostate cancer after radical prostatectomy. J. Clin. 
Oncol. 25, 2035–2041.
Trock, B. J., Han, M., Freedland, S. J., Humphreys, E. B., 
DeWeese, T. L., Partin, A. W., and Walsh, P. C. (2008). 
Prostate cancer-specific survival following salvage 
radiotherapy vs observation in men with biochemi-
cal recurrence after radical prostatectomy. JAMA 299, 
2790–2769.
Wiegel, T., Bottke, D., Steiner, U., Siegmann, A., Golz, 
R., Störkel, S., Willich, N., Semjonow, A., Souchon, 
R., Stöckle, M., Rübe, C., Weissbach, L., Althaus, P., 
Rebmann, U., Kälble, T., Feldmann, H. J., Wirth, M., 
Hinke, A., Hinkelbein, W., and Miller, K. (2009). Phase 
III postoperative adjuvant radiotherapy after radical 
prostatectomy compared with radical prostatectomy 
alone in pT3 prostate cancer with postoperative unde-
tectable prostate-specific antigen: ARO96-02/AUO 
AP 09/95. J. Clin. Oncol. 27, 2924–2930.
Received: 10 September 2012; accepted: 11 September 2012; 
published online: 27 September 2012.
Citation: Shilkrut M, Feng F and Hamstra DA (2012) 
General commentary to the “Management of biochemi-
cal recurrence after primary localized therapy for prostate 
cancer”  by Darwish O. M. and Raj G. V. Front. Oncol. 
2:126. doi:10.3389/fonc.2012.00126
This article was submitted to Frontiers in Genitourinary 
Oncology, a specialty of Frontiers in Oncology.
Copyright © 2012 Shilkrut, Feng and Hamstra. This is 
an open-access article distributed under the terms of the 
Creative Commons Attribution License, which permits 
use, distribution and reproduction in other forums, pro-
vided the original authors and source are credited and 
subject to any copyright notices concerning any third-party 
graphics etc.
